Modeling the response to interleukin-21 to inform natural killer cell immunotherapy

Immunology & Cell Biology. doi: 10.1111/imcb.12848

Human-correlated genetic models identify precision therapy for liver cancer

Nature. doi: 10.1038/s41586-025-08585-z

A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinoma

Disease Models & Mechanisms. doi: 10.1242/dmm.052301

Abstract B135: Activity of Tegavivint in Hepatocellular Carcinoma with Aberrant Wnt/β-catenin Signaling and Evaluation of Biomarker Response

Molecular Cancer Therapeutics. 

PixlMap: A generalisable pixel classifier for cellular phenotyping in multiplex immunofluorescence images

PLoS One. doi: 10.1371/journal.pone.0317865

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2024.12.016

Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcome 

JHEP Reports. doi: 10.1016/j.jhepr.2025.101637

Loss of p62 Binding Allows TIF-IA Accumulation in Senescence, Which Promotes Phenotypic Changes to Nucleoli and the Senescence Associated Secretory Phenotype

Aging Cell. doi: 10.1111/acel.70334

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma

bioRxiv preprint. doi: 10.1101/2025.07.08.663653

Spatial lipidomics reveals sphingolipid metabolism as anti-fibrotic target in the liver

Metabolism. doi: 10.1016/j.metabol.2025.156237

Pharmacological manipulation of liver fibrosis progression using novel HDAC6 inhibitors

The FEBS Journal. doi: 10.1111/febs.70062

Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening

Hepatology Communications. doi: 10.1097/HC9.0000000000000706

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis

bioRxiv preprint. doi: 10.1101/2025.05.06.652454

Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2025.08.042

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2025.07.033

Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

ESMO Open. doi: 10.1016/j.esmoop.2025.105065

British Society of Gastroenterology hepatocellular carcinoma guideline review: impact on the frontline

Hepatology Guideline review. doi: 10.1136/flgastro-2024-102927

CIA: unveiling cellular identities with cluster- independent annotation in single-cell RNA sequencing data for comprehensive cell type characterization and exploration

BMC Bioinformatics. doi: 10.1186/s12859-025-06320-z

Secretory IgA amplification during immune checkpoint blockade enhances the control of tumor growth by enterotropic T cells

Science Advances. doi: 10.1126/sciadv.aeb5308

Dual Activation-Induced Marker Combinations Efficiently Identify and Discern Antigen-Specific and Bystander-Activated Human CD4+ T Cells

European Journal of Immunology. doi: 10.1002/eji.202451404

Prolonged persistence of mutagenic DNA lesions in somatic cells

Nature. doi: 10.1038/s41586-024-08423-8

E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-25-0725

Hepatocellular carcinoma: Epidemiology, diagnosis and treatment

JHEP Reports. doi: 10.1016/j.jhepr.2025.101571

Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma

JHEP Reports. doi: 10.1016/j.jhepr.2025.101592

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology. doi: 10.1002/1878-0261.70168

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Liver Cancer. doi: 10.1159/000549565